Pharmafile Logo

Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care

September 24, 2025 |  

Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.

Voices-of-Oncology-Inizio

With over 30 years of deep-rooted expertise in oncology, we partner with our clients at each pivotal moment in their journey, unlocking value through a connected suite of capabilities. Today, we’re proud to announce that a number of our leaders in Inizio have been featured in Forbes’ Voices of Oncology, a collaboration that reflects our commitment to advancing cancer care.

Launching September 9, the ‘Voice of Innovation Partners’ chapter in Forbes’ ‘Voices of Oncology’ features contributions from:

Accelerating innovation in oncology through collaboration, data & technology

The ‘Voice of Innovation Partners’ chapter explores how innovation partners like Inizio harness advanced data analytics, cutting-edge technology, and cross-sector collaboration to:

  • Simplify complex challenges in oncology
  • Enhance decision-making across the cancer care continuum
  • Improve patient outcomes through real-world impact

The book is a powerful collection of insights from global experts and thought leaders, offering a shared perspective on how we can work better together to shape the future of oncology. Voices of Oncology is an initiative of the Oncology Voice Network (OVN), a new platform built to spark connection, share knowledge, and amplify solutions across pharma, biotech, academia, and patient advocacy.

Pre-order now: Forbes’ Voices of Oncology

Available to pre-order now via Amazon – explore the Voices of Oncology here. If you’re looking for a partner who can turn knowledge into action and accelerate the journey from breakthrough science to real-world impact, learn more about us.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.

Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer

With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.

Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI

Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.

Article: Creating truly effective communications – the impact of high speed, high octane messaging

In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.

Research Partnership makes two senior appointments to bolster its US and MedTech operations

Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.

Case study: How segmentation of treaters guided a novel product launch in the allergy space

Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment...

Article: War in the Blood – The battle takes shape in the burgeoning European oncology CAR-T market access space

Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.